Evidence map›Paper›PMID 25975970›Full record

ArticleJournal of clinical immunology2015

A novel pathogenic variant in PRF1 associated with hemophagocytic lymphohistiocytosis.

Camilo Andrés Pérez Romero, Isaura Pilar Sánchez, Sebastian Gutierrez-Hincapié, Jesús A Álvarez-Álvarez, Jaime Andres Pereañez, Rodrigo Ochoa, Carlos Enrique Muskus-López, Ruth G Eraso, Carolina Echeverry, Catalina Arango and 2 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Journal of clinical immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Case Report:Frontiers in immunology · 2025
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Camilo Andrés Pérez RomeroGrupo de Inmunodeficiencias Primarias, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.
Isaura Pilar Sánchez
Sebastian Gutierrez-Hincapié
Jesús A Álvarez-Álvarez
Jaime Andres Pereañez
Rodrigo Ochoa
Carlos Enrique Muskus-López
Ruth G Eraso
Carolina Echeverry
Catalina Arango
José Luis Franco Restrepo
Claudia Milena Trujillo-Vargas
Universidad de Antioquia · COHospital Pablo Tobon Uribe · COHospital Universitario de San Vicente Fundación · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Familial Hemophagocytic Lymphohistiocytosis type 2 (FHL2) results from mutations in PRF1. We described two unrelated individuals who presented with FHL, in whom severely impaired NK cytotoxicity and decrease perforin expression was observed. DNA sequencing of PRF1 demonstrated that both were not only heterozygous for the p.54R > C/91A > V haplotype but also presented with the novel variant p.47G > V at the perforin protein. Perforin mRNA was found to be increased in a individual with that genotype. A carrier of the novel variant also demonstrated altered perforin mRNA and protein expression. Phylogenetic analysis and multiple alignments with perforin orthologous demonstrated a high level of conservation at Gly47. PolyPhen-2 and PROVEAN predicted p.47G > V to be "probably damaging" and "deleterious", respectively. A thermodynamic analysis showed that this variant was highly stabilizing, decreasing the protein internal energy. The ab initio perforin molecular modeling indicated that Gly47 is buried inside the hydrophobic core of the MACPF domain, which is crucial for the lytic pore formation and protein oligomerization. After the in silico induction of the p.47G > V mutation, Val47 increased the interactions with the surrounding amino acids due to its size and physical properties, avoiding a proper conformational change of the domain. To our knowledge, this is the first description supporting that p.47G > V is a pathogenic variant that in conjunction with p.54R > C/91A > V might result in the clinical phenotype of FHL2.

Indexed as

Cytotoxicity, ImmunologicAdolescentAdultChildChild, PreschoolComputational BiologyDown-RegulationFemaleHumansInfantKiller Cells, NaturalLymphohistiocytosis, HemophagocyticMaleMiddle AgedMutationPedigreePerforinPRF1 protein, human

Identifiers

PMID25975970
OpenAlexW2460596259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.